Epigenetic Company EpigenCare Debuts $99 Version of its SKINTELLI Personalized Skincare DNA Test

FARMINGDALE, N.Y., December 23, 2020 —EpigenCare Inc., a biotechnology company specializing in consumer epigenetics, launched its new version of its SKINTELLI personalized skincare test. The product, which is a direct-to-consumer DNA test, looks at the current quality of an individual’s skin through epigenetic mechanisms such as DNA methylation. This new version, dubbed the “Standard” tier, is offered at a $99 price point, significantly lower than its first version that is priced at $399.

The original SKINTELLI test, now classified as the “Advanced” option, uses next-generation sequencing to determine the activity levels of one’s genes that are responsible for multiple skin quality aspects including skin aging, moisture retention, and pigmentation. The new test uses a methylation-specific PCR method that has particularly weight in its algorithm on skin aging, from which other additional quality factors can be derived from in a cost-effective manner. This more affordable method also significantly decreases expected turnaround time while still maintaining accurate results.

In late 2019, EpigenCare successfully validated its algorithm model of accurately measuring epigenetic aging through a participant study during its early beta phase. After gathering aggregate data in 2020 and refining its data model, the company now also offers a free questionnaire-based product that correlates users’ answers to its lab data via artificial intelligence. Subsequently, three tiered options are now offered: Basic, Standard, and Advanced, with the latter being the most comprehensive version of the test.

“We have long recognized that a hurdle to consumers was price. With the innovative development of a $99 solution, we are now more in line with the general DNA testing segment while offering significantly more value by assessing current epigenetic factors as opposed to static genetic predispositions,” said William Lee, EpigenCare’s CEO. “Combined with accelerated turnaround time, we expect user adoption to rapidly increase in 2021.”

The proprietary SKINTELLI epigenetic skincare test, combined with an ingredient-based matching algorithm, provides a scientifically driven solution to reduce trial-and-error spending on sub-optimal skincare products. EpigenCare will also be releasing an iOS app in early 2021 as it awaits its pending app store application with Apple to be completed. You can get started for free with a personalized skincare quiz at https://www.skintelli.com.

About EpigenCare
EpigenCare Inc. is a privately held personal epigenomics and digital biotechnology company based in New York. The company offers SKINTELLI, a direct-to-consumer epigenetics test to assess the dynamic state of one’s skin quality and match it to existing skincare brands on the market. EpigenCare is a winner of Johnson & Johnson’s Digital Beauty Quickfire Challenge and its epigenetic technology is supported by EpiGentek Group Inc. Both investors and consumers can learn more about EpigenCare and its personalized skincare solutions at https://www.epigencare.com as well as https://www.skintelli.com regarding its SKINTELLI product.

Note: This release includes forward-looking statements by the Company.

Initial Beta Phase Results in for Epigenetic-based Personalized Skincare Testing Company EpigenCare

FARMINGDALE, N.Y., Sept. 12, 2019 — Epigenetic biotechnology company EpigenCare Inc. recently completed its initial pilot study with its direct-to-consumer epigenetic skincare test as part of its beta phase. Its test, SKINTELLI (https://www.skintelli.com), was made available in a limited release since March of this year to qualifying early adopters. Preliminary findings enabled EpigenCare to develop a statistical model for approximating the age of an individual’s skin, irrespective of his or her chronological age.

The SKINTELLI test uses next-generation sequencing to quantitate the activity levels of one’s genes that are responsible for multiple skin quality aspects including skin aging, moisture retention, and pigmentation. These active or inactive states are determined by the DNA methylation levels of a proprietary panel of gene markers using a modified targeted bisulfite-sequencing and bioinformatics method. DNA methylation is the most well characterized epigenetic mechanism and can be used to assess one’s current skin quality as opposed to static genetic predispositions commonly found in current DNA genotyping tests.

During the first part of the beta phase, EpigenCare found that the skin ages measured based on its proposed model is consistent with the methylation levels of the age-focused gene marker panel and are also highly correlated with the chronological ages of most individuals, suggesting the capability for the model to identify individuals with atypical skin quality. The most frequent skin quality factors with minor adverse impact are skin sensitivity response control (73.9% of participants) followed by skin rejuvenation capability (47.8%) and moisture retention (30.4%). These results were recently presented by the company’s CEO, William Lee, at the Innovations in Dermatological Sciences meeting hosted by Rutgers University’s Center for Dermal Research.

“Through SKINTELLI, we intend to accelerate the implementation of epigenetics in consumer applications,” said Dr. Adam Weiwei Li, CSO at EpigenCare, “through rapid data accumulation and validation of DNA methylation changes in key markers of skin quality.”

By offering a scientifically driven solution that is informative to the consumer, one can reduce trial-and-error spending on skincare products with EpigenCare’s ingredient-based matching algorithm. The company plans for a larger sample pool of participants in the next stage of its beta phase and is currently enroute for official debut of SKINTELLI next year.

About EpigenCare
EpigenCare Inc. is a privately held personal epigenomics and digital biotechnology company based in New York. The company offers SKINTELLI, a direct-to-consumer epigenetics test to assess the dynamic state of one’s skin quality and match it to existing skincare brands on the market. EpigenCare is a winner of Johnson & Johnson’s Digital Beauty Quickfire Challenge and its epigenetic technology is supported by EpiGentek Group Inc. Both investors and consumers can learn more about EpigenCare and its personalized skincare solutions at https://www.epigencare.com.

Note: This release includes forward-looking statements by the Company.

For media contact, please e-mail media[at]epigencare.com.

EpigenCare Launches Limited Beta Release of its Personal Epigenetic Skincare Test SKINTELLI

FARMINGDALE, N.Y., February 12, 2019 – EpigenCare Inc., a biotechnology company focused on consumer epigenetics, publicly launched today its beta-stage product for personalized skincare called SKINTELLI (https://www.skintelli.com/). The product is the first direct-to-consumer epigenetic test on the market to assess the dynamic qualities of a consumer’s skin. SKINTELLI specifically looks at a panel of epigenetic marks that determine the “active” states of genes responsible for multiple skin quality factors, some of which include aging, moisture retention, and anti-oxidation.

Epigenetic changes are naturally occurring mechanisms with age, but can be greatly impacted by lifestyle choices including sun exposure and product ingredients applied to one’s skin. Unlike genetic tests that only look at static predispositions, SKINTELLI can profile a consumer’s current skin quality and assess the changes over time with repeatable tests. Moreover, the consumer will be matched with skincare products on the market, ranging from name brand to indie-boutique, that are best-suited for the current state of his or her skin. Because epigenetic changes are reversible, EpigenCare’s profile-to-product matching system can potentially save a consumer thousands of dollars each year by mitigating trial-and-error shopping habits.

During this limited beta release, the SKINTELLI test will be made available first to early backers, pre-orderers, waitlisted individuals, and select invitees. Any remaining inventory will be made available to the general public, or otherwise be placed on its second round of pre-orders. EpigenCare hopes to generate field insight and data during this phase in order to improve its offerings before the eventual full launch.

“Our technology has been years in the making,” said William Lee, EpigenCare’s CEO. “We are very excited to finally fulfill the first set of orders as we move into the forefront of consumer epigenetics.”

The company expects high demand for SKINTELLI as it gets closer to full public release later this year. A survey that EpigenCare commissioned last fall showed that 91% of respondents are dissatisfied with their current skincare routine or think it could be better, while 93% would be interested in biologically measuring the progress of their skincare regimen. Recently, EpigenCare increased its proprietary markers from 26 to 40 and also filed its patent “A method of creating an epigenetic skin profile associated with skin quality” in July of last year.

About EpigenCare
EpigenCare Inc. is a privately held personal epigenomics and digital biotechnology company based in New York. The company offers SKINTELLI, a direct-to-consumer epigenetics test to assess the dynamic state of one’s skin quality and match it to existing skincare brands on the market. EpigenCare is a winner of Johnson & Johnson’s Digital Beauty Quickfire Challenge and its epigenetic technology is supported by EpiGentek Group Inc. Both investors and consumers can learn more about EpigenCare and its personalized skincare solutions at https://www.epigencare.com.

Note: This release includes forward-looking statements by the Company.

For media contact, please e-mail media[at]epigencare.com.

EpigenCare Files Patent for Epigenetic Testing Towards Personalized Consumer Skincare

FARMINGDALE, N.Y., July 19, 2018 — EpigenCare Inc., a skincare matching platform based on an at-home test for epigenetic markers of the skin, announced today the filing of its patent application, “A method of creating an epigenetic skin profile associated with skin quality.” Specifically, the patent outlines a technique to develop a skin profile from biological samples through epigenetic markers that are associated with skin quality.

EpigenCare’s prototype test kit.

The patent application involves a non-invasive sample collection method from the surface of the skin to be subsequently assessed for the epigenetic states through methylation-specific sequencing. A panel of epigenetic markers associated with skin quality and appearance is specifically measured for their DNA methylation levels to generate an individualized profile of the current quality of one’s skin.

The first inventor of the method, Dr. Adam Li, Chief Scientific Officer at EpigenCare, said: “The filing indicates EpigenCare’s intention to develop a strong intellectual property portfolio, which will effectively protect the unique innovation of our epigenetic skin test when it enters the retail market.”

Epigenetics is the study of biological mechanisms that can turn genes on or off. These mechanisms can be influenced by the environment, including the ingredients contained in skincare products. Because skin quality is highly individualized and dynamic, a robust panel of epigenetic markers provides a powerful measuring tool for skincare regimen progress as well as for optimizing one’s skincare routine.

EpigenCare’s CEO William Lee states, “Other companies have exploited consumer epigenetics in an irresponsible manner, and we intend to put an end to this. This patent application demonstrates our commitment to grounded science when it comes to consumer’s concerns.”

The New York-based organization is the first company to use epigenetics to develop consumer skin quality profiles and use an ingredient-based A.I. system to match existing products on the market to the profiles. It recently won a digital beauty competition hosted by Johnson & Johnson Innovation and is currently in its fundraising stage. It is currently wrapping up a pre-seed Regulation CF offering to the public at https://www.startengine.com/epigencare before entering private investment rounds.

About EpigenCare
EpigenCare Inc. is a privately held personal epigenomics and digital biotechnology company based in New York. The company offers a direct-to-consumer epigenetics test to assess the dynamic state of one’s skin type and quality. Subsequently, capture of the dynamic quality allows for actionable results from the analysis report such that optimized product options are recommended to the consumer. EpigenCare’s epigenetic technology is supported by EpiGentek Group Inc. Both investors and consumers can learn more about EpigenCare and its personalized skincare solutions at https://www.epigencare.com.

Note: This release includes forward-looking statements by the Company.

For media contact, please e-mail media[at]epigencare.com.

EpigenCare Announced as a Winner in Digital Beauty QuickFire Challenge for Skin Care

FARMINGDALE, N.Y., April 4, 2018 – Personalized skincare technology startup EpigenCare Inc. announces it is a winner of the Johnson & Johnson Innovation competition for innovative skincare technologies. The Digital Beauty QuickFire Challenge was intended to discover some of the future-forward digital beauty solutions, particularly in personalization tools that would help consumers make better informed skincare regimen decisions.

EpigenCare’s CEO and co-founder, William Lee, presented at the Johnson & Johnson Innovation, JLABS (JLABS) open innovation ecosystem in South San Francisco, CA. The presentation included information on the forefront of science and technology — epigenetics, blockchain, and artificial intelligence. Lee emphasized the problem of consumers not knowing whether a skincare product is truly working for them, and that static genetic variants in current personal genomic tests cannot be altered by product ingredients. The presentation introduced a solution via epigenetics, which can determine the active or inactive state of a gene’s function.

EpigenCare presents its personalized skincare and blockchain privacy protection technologies at JLABS in San Francisco.

The New York-based company will be releasing a direct-to-consumer skincare test later this year that can capture the current state of one’s skin profile by sequencing for epigenetic markers. These markers are correlated with quality indicators such as aging, elasticity, moisture, pigmentation, and more. EpigenCare’s complementary digital platform subsequently connects products from skincare companies to consumers on a personalized basis through a matching algorithm, based on the ingredient’s epigenetic intervention on the tested markers and their functional pathways.

In order to ensure consumer privacy, blockchain technology will be deployed to manage data in a responsible manner. Consumers will be able to track that their data was used for their own benefit. This will drastically mitigate the perceived intrusiveness often associated with personal tests involving DNA, which consumers will self-collect directly on their own skin through a non-invasive adhesive method.

EpigenCare also plans to implement machine learning with its epigenetic data, which serves as a scientifically grounded training source, to be combined with photo imaging of skin for an artificial intelligence based personalization method.

“I am grateful for the opportunity that we have been provided,” said Lee. “It is clear that Johnson & Johnson Innovation actively supports new technologies through its open innovation model. We intend to use this victory to continue our momentum in realizing a truly personalized skincare solution.”

The QuickFire Challenge awarded up to $50,000 in grants, access to a network of experts and mentorship, residency for up to one year at a JLABS location, with admission to test the product with consumers at the Johnson & Johnson Consumer Experience Center (CxC). EpigenCare was one of two winners that split the prize.

About EpigenCare
EpigenCare Inc. is a privately held personal epigenomics and digital biotechnology company based in New York. The company offers a direct-to-consumer epigenetics test to assess the dynamic state of one’s skin type and quality. Subsequently, capture of the dynamic quality allows for actionable results from the analysis report such that optimized product options are recommended to the consumer. EpigenCare’s epigenetic technology is supported by EpiGentek Group Inc. Both investors and consumers can learn more about EpigenCare and its personalized skincare solutions at https://www.epigencare.com.

Note: This release includes forward-looking statements by the Company.

For media contact, please e-mail media[at]epigencare.com.

EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challenge

FARMINGDALE, N.Y., March 22, 2018 – EpigenCare Inc., a personalized skincare startup company, has been named by Johnson & Johnson Innovation as a finalist in its Digital Beauty Quickfire Challenge. The challenge is designed to identify, recognize, and support the most innovative and future-forward digital beauty solutions. One of the key innovation areas that the challenge focuses on is personalization tools to simplify product selection and build regimen in a way that empowers consumers to make better informed skincare choices.

EpigenCare has developed a direct-to-consumer skincare test that assesses the current state of one’s skin by looking at epigenetic markers associated with quality indicators including aging, elasticity, moisture, pigmentation, and more. Epigenetics is the study of biological mechanisms (e.g., DNA methylation) that could activate or deactivate a gene’s function over time. Since a person has the same genes throughout his or her entire life, only epigenetic — rather than genetic — profiling could accurately reflect the dynamic and current state of one’s skin.

The company is currently working on a complementary digital platform that skincare companies can use to match their existing products to consumers on a personalized basis. The matching process is through a recommendation algorithm based on the epigenetic effects of product ingredients on the consumers’ tested epigenetic markers of their skin.

To ensure consumers’ privacy is protected, EpigenCare is implementing blockchain technology on the digital platform such that consumers are designated with a blockchain transaction ID rather than with any personally identifiable information. The company’s business model is for consumer data to be used only for one’s exclusive benefit in the form of personalized products. Through the decentralized blockchain ledger, consumers can choose to audit how their data is being used, thereby eliminating the perceived intrusiveness often associated with direct-to-consumer tests requiring DNA. EpigenCare also plans to implement machine learning with its epigenetic data, which can be combined with photo imaging of skin for an artificial intelligence based personalization method.

“True innovation doesn’t just elevate product experiences and outcomes—it challenges the very definition of skin care itself,” said Sebastien Guillon, President, Global Beauty, Johnson & Johnson Consumer Inc. “The next beauty tech disrupters are out there, and this Challenge will help us identify the most promising potential partners in the co-creation of meaningful, future-forward skin solutions.”

EpigenCare will present at the JLABS technology center in San Francisco, CA on March 27th. In addition to a $50,000 grant, Johnson & Johnson Innovation will provide winners with access to a network of experts, residency for up to one year at JLABS incubator, and admission to a Johnson & Johnson Consumer Experience Center (CxC). Winners will be able to design and deploy a research initiative through the CxC.

The company’s CEO and co-founder, William Lee, said, “It is an honor for EpigenCare to be recognized as an innovative organization. We are committed to bringing cutting-edge science in helping consumers identify skincare products that are best suited for their skin.”

Johnson & Johnson Innovation is also hosting voting process for a social award that is separate from the main award. You can watch Lee’s two minute presentation video and vote for EpigenCare until March 25th towards the People’s Choice Award at: https://jlabs.jnjinnovation.com/quickfire-challenges/digital-beauty

About EpigenCare
EpigenCare Inc. is a privately held personal epigenomics and digital biotechnology company based in New York. The company offers a direct-to-consumer epigenetics test to assess the dynamic state of one’s skin type and quality. Subsequently, capture of the dynamic quality allows for actionable results from the analysis report such that optimized product options are recommended to the consumer. EpigenCare’s epigenetic technology is supported by EpiGentek Group Inc. Learn more about EpigenCare and its personalized skincare solutions at https://www.epigencare.com. Investors interested in EpigenCare can learn more about its business model and opportunities at https://token.epigencare.com/

Note: This release includes forward-looking statements by the Company.

For media contact, please e-mail media[at]epigencare.com.

EpigenCare’s Personalized Skincare Test Brings Epigenetics Closer to Consumer Application

FARMINGDALE, N.Y.March 15, 2018 – EpigenCare Inc., a startup company for personalized skincare based on epigenetic testing, disclosed its intentions to bring epigenetics into mass consumer adoption through big data accumulation, bioinformatics, and machine learning. In contrast to a rising number of companies that improperly exploit the field of epigenetics in a pseudo-scientific manner, EpigenCare will generate data through consumer use of EpigenCare’s upcoming direct-to-consumer skincare test and high-throughput sequencing in its lab. This strategy will provide significant insight into epigenetic correlators and data points, thereby fast-tracking research in a field that has long been confined to limited studies in academia.

Identical twins have the exact same genetic sequence, yet will have entirely different DNA methylation levels (an epigenetic mechanism), which can be reflected in the skin quality.

Current personalization of skincare is largely based on consultation and genetic testing. Without a scientifically-grounded test to assess skin properties, consultation-based solutions can only identify a few skin types on a superficial basis. This approach is typically too generalized such that most individuals receive very similar product recommendations for skincare. As for genetic-based tests, these methods often rely on a gene’s single-nucleotide polymorphism (SNP). SNPs are established at birth and cannot be altered or reversed during one’s entire life and thusthey are unable to represent the dynamic changes of functional pathways which will affect skin quality states.

The company has developed a personal skincare test which, using a methylation-specific next-generation sequencing technique, looks at a panel of epigenetic markers strongly correlated with and dynamically reflects skin quality indicators including aging, firmness and elasticity, moisture retention, pigmentation, and others. The captured skin profile can be used for selection of skincare products best suited for the skin’s current state through EpigenCare’s ingredient-based matching algorithm.

Epigenetic-based skin profiling is being increasingly recognized as the only viable solution for both personalized and practical skincare since epigenetics, not genetics, determines dynamic changes of skin quality in response to different environment stimuli. EpigenCare’s initial panel of epigenetic markers was validated in its lab with the assistance of EpiGentek, a related reagent supplier and service provider for epigenetic research.

Increasingly better bioinformatics tools and affordable next-generation sequencing, as well as overall rise in computing power, have become powerful accelerators of epigenetic research versus slower benchwork that is often of a more narrow scope. EpigenCare believes that offering a strong value proposition to consumers through its skincare test will rapidly provide the company with data that can be subsequently leveraged by artificial intelligence. Such A.I. could be used to refine epigenetic markers, validate the role of epigenetics against new data points, and ultimately combine photos of one’s skin with predictive modeling to provide low cost personalization solutions.

“Our ability to accumulate mass amounts of epigenetic skin data,” says Dr. Adam Li, EpigenCare’s Chief Scientific Officer, “means that we are taking a step closer towards widespread consumer applications of epigenetics by using big data and algorithmic data processing. Big data of epigenetic information on skin will provide actual scientific basis used for machine-learning. Such artificial intelligence, combined with photo imaging, would be truly useful for identifying skin quality states in a simplified manner.”

Through its strategy to gather epigenetic skin profiles, EpigenCare is attracting the interest of high profile skincare companies with its platform. They will eventually be able to use EpigenCare’s platform and its recommendation algorithm in order to match skincare products to the consumer in a scientifically personalized manner. EpigenCare is also addressing the consumer’s privacy concerns using blockchain technology. Since blockchain ledgers are tamperproof and cannot be changed or hacked, consumers will be able to transparently verify that their data is being used only for their own benefit.

Investors interested in EpigenCare can learn more about its business model and opportunities at https://token.epigencare.com/

About EpigenCare
EpigenCare Inc. is a privately held personal epigenomics and digital biotechnology company based in New York. The company offers a direct-to-consumer epigenetics test to assess the dynamic state of one’s skin type and quality. Subsequently, capture of the dynamic quality allows for actionable results from the analysis report such that optimized product options are recommended to the consumer. EpigenCare’s epigenetic technology is supported by EpiGentek Group Inc. Learn more about EpigenCare and its personalized skincare solutions at www.epigencare.com.

Note: This release includes forward-looking statements by the Company.

For media contact, please e-mail media[at]epigencare.com.

EpigenCare is Disrupting the Skincare Industry through Epigenetics and Blockchain

FARMINGDALE, N.Y., Feb. 19, 2018 — EpigenCare Inc. has revealed the world’s first project for truly personalized skincare based on epigenetics and blockchain technology. The biotechnology company’s digital platform will connect consumers with skincare companies using a scientific matching algorithm based on the consumer’s epigenetic profile and a product’s active ingredients. By amassing dynamic and scientifically-grounded skin profiles, EpigenCare introduces a brand new marketing channel for the $130 billion skincare industry.

Direct-to-Consumer Testing
EpigenCare developed a personal epigenomics test to generate epigenetic skin profiles that correlate with key skin quality indicators (e.g., aging, elasticity, moisture retention, etc.). Through a simple and non-invasive sample collection kit, the DNA samples used for the test are self-collected directly from consumers’ skin in the comfort of one’s own home. The samples are subsequently mailed to EpigenCare’s facilities for testing via a proprietary next-generation sequencing based application.

Because epigenetics, not genetics, functionally determines the dynamic state of skin, EpigenCare’s test most accurately reflects the true state of one’s skin quality in a quantifiable manner. Moreover, epigenetics allows EpigenCare to implement a recurring business model by helping consumers track the progress of their skincare routine’s effectiveness on their skin.

Recommendation Engine
The company is indexing the ingredients of thousands of skincare products, ranging from name brand to boutique. EpigenCare’s matching algorithm will then select the ingredients that epigenetically impact the consumer’s tested skin quality indicators in a positive manner. The ingredient selections are subsequently checked against the product database for the skincare products that have an optimal ingredient composition, which are finally presented as recommendations in the consumer’s skincare test report. EpigenCare will offer the first direct-to-consumer test that contains specific, actionable results.

A Blockchain Ecosystem
Through EpigenCare’s web platform named “The EpigenCare Network”, skincare companies will be able to leverage the scientific-matching mechanism of the recommendation engine. These companies will target epigenetic profile segments with the opportunity to place their auto-screened products in the recommendation section of the consumer’s test results.

Developed on the Ethereum blockchain, this platform rewards consumers that have been targeted by companies with tokens that can be used to subsidize future skincare tests. Because of the “anonymous transparency” of blockchains, EpigenCare is able to address the commonly perceived intrusiveness often associated with the likes of 23andMe and Ancestry.com tests.

EpigenCare’s CEO, William Lee, said, “By building a structured ecosystem with blockchain technology, consumers will be able to know that any data of theirs being sold is directly, voluntarily, and exclusively for their own benefit.”

Investment Offering
EpigenCare is launching an Initial Coin Offering (ICO) to the public for its tokens in mid-March, seeking to raise $20 million USD (https://token.epigencare.com). It is one of the only ICOs to offer a token as a security through a Regulation D* exemption filing with the SEC, thus giving the company legal capability to pay dividends to investors based on revenue.

*Available for US accredited investors who undergo a KYC/whitelisting process.

Disruptive Innovation
EpigenCare is transforming the skincare industry by strategically commoditizing consumer skin profiles in a way that directly benefits consumers. As gatekeepers of such new data, EpigenCare’s model will prompt skincare companies to market and produce products with more scientific transparency and true consumer personalization.

The company’s industry advisor Richard Wildnauer, former CEO of NeoStrata and VP at Johnson & Johnson, expressed his enthusiasm for the innovation.

“This revolutionary business model promises to uniquely take advantage of the rapidly developing fields of epigenetics and blockchain,” said Wildnauer, “to develop a database to solve the problem of product selection for personalized targeted skin care. It reduces the costs and frustrations of multiple product trials by consumers, provides cosmetic companies with another tool to guide product development, and provides a basis for monetization by the consumer participants and EpigenCare.”

About EpigenCare
EpigenCare Inc. is a privately held personal epigenomics and digital biotechnology company based in New York. The company offers a direct-to-consumer epigenetics test to assess the dynamic state of one’s skin type and quality. Subsequently, capture of the dynamic quality allows for actionable results from the analysis report such that optimized product options are recommended to the consumer. EpigenCare’s epigenetic technology is supported by EpiGentek Group Inc.

Note: This release includes forward-looking statements by the Company.

For media contact, please e-mail media[at]epigencare.com.